Fred Alger Management Adds $69M in Johnson & Johnson ($JNJ)
The fund added 269,777 shares of Johnson & Johnson, increasing its holdings by 416% to 334,592 shares.
Key Points
- Fred Alger Management increased its stake in Johnson & Johnson by 416%, adding 269,777 shares to hold a total of 334,592 shares valued at $80.6 million.
- Johnson & Johnson, trading at $241 on Thursday, has a market cap of $556.8 billion, with a P/E ratio of 26.8 and a 52-week range of $149.74 to $251.71.
- Insider Kathryn Wengel sold 10,000 shares on June 11, 2026, while analysts like Leerink Partners upgraded the stock to 'buy' with a $265 target.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Fred Alger Management has increased its stake in Johnson & Johnson (NYSE:JNJ) by a notable 416%, according to its latest Form 13F filing with the SEC. The fund added 269,777 shares during the reporting period, bringing its total holdings to 334,592 shares, valued at approximately $80.6 million.
Fred Alger Management vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Fred Alger Management's Johnson & Johnson Position
Fred Alger Management boosted its investment in Johnson & Johnson significantly, increasing its holdings by 416%. The fund went from owning 64,815 shares to 334,592 shares, adding 269,777 shares in the process. This substantial increase reflects a strong vote of confidence in the healthcare giant.
Other Institutional Activity in Johnson & Johnson
Several other institutional investors also made moves in Johnson & Johnson. BlackRock, Inc. increased its holdings by 4.6 million shares, ending with 213.4 million shares valued at about $52.2 billion, a 2.2% increase. Vanguard Capital Management LLC opened a new position with 156.6 million shares worth approximately $38.3 billion. State Street Corp trimmed its stake by 393,555 shares to 133.5 million shares, a slight 0.3% decrease in holdings. JPMorgan Chase & Co expanded its position by 4.5 million shares, now holding 63.1 million shares valued at $15.3 billion, marking a 7.7% increase.
Johnson & Johnson Stock Down 5.2%
Shares of Johnson & Johnson traded around $241 on Thursday. The company boasts a market capitalization of about $556.8 billion, with a P/E ratio of 26.8 and a forward P/E of 18.2. Its stock has a 52-week low of $149.74 and a high of $251.71. The 50-day moving average stands at $230.37, while the 200-day moving average is $215.73. Johnson & Johnson maintains a current ratio of 1.03 and a quick ratio of 0.69, with a debt-to-equity ratio of 67.73.
$JNJ stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Johnson & Johnson reported revenues of $96.36 billion, reflecting a growth rate of 9.9%. The company's net margin was 21.8%, and it achieved a return on equity of 26.4%. Earnings per share stood at $8.63. The next earnings report is scheduled for July 15, 2026.
Dividend
Johnson & Johnson offers an annual dividend rate of $5.36, yielding 2.35%. The company's dividend payout ratio is 60.25%.
Insider Buying and Selling at Johnson & Johnson
On June 11, 2026, Kathryn Wengel, EVP and Chief TO and Risk Officer, sold 10,000 shares at an average price of $241.15. On the same day, she also bought 10,000 shares at $115.67. Other insider transactions include Marillyn Hewson purchasing 215 shares, Eugene Woods buying 161 shares, and Daniel Pinto acquiring 134 shares, all at $232.79 on June 9, 2026.
Analysts Set New Price Targets
On May 13, 2026, Leerink Partners upgraded Johnson & Johnson to a 'buy' rating with a price target of $265. Barclays maintained its 'hold' rating with a $255 target on April 15, 2026. Wells Fargo also maintained a 'buy' rating with a $263 target. The consensus among 23 analysts is a 'buy', with a mean price target of $252.87.
About Johnson & Johnson
Johnson & Johnson is a global leader in healthcare, focusing on research, development, and manufacturing of innovative products. Based in New Brunswick, New Jersey, the company operates through its Innovative Medicine and MedTech segments. It provides a range of products across therapeutic areas like oncology, immunology, and cardiovascular health. The company, led by CEO Joaquin Duato, employs about 138,200 people worldwide.
Bottom Line
Fred Alger Management's substantial increase in its Johnson & Johnson holdings reflects a strong belief in the company's prospects. With a solid market position and promising financials, Johnson & Johnson remains a closely watched stock. As always, note that 13F filings are historical and may not represent current positions.
Get Johnson & Johnson alerts
New 13F filings, insider trades, and analyst moves on $JNJ, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.